

April 19, 2021

The Honorable Rosa DeLauro
Chairwoman
House Appropriations Committee
2413 Rayburn House Office Building
Washington, DC 20510

The Honorable Kay Granger
Ranking Member
House Appropriations Committee
1026 Longworth House Office Building
Washington, DC 20510

The Honorable Betty McCollum
Chairwoman
Subcommittee on Defense
2256 Rayburn House Office Building
Washington, DC 20510

The Honorable Ken Calvert
Ranking Member
Subcommittee on Defense
2205 Rayburn House Office Building
Washington, DC 20510

Dear Members of the Appropriations Committee:

As members of the Global Health Technologies Coalition (GHTC)—a group of 37 nonprofit organizations, academic institutions, and aligned businesses advancing policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people—we write to highlight the critical role of US programs that support global health research and development (R&D) and thank you for your support of important R&D at the US Department of Defense (DoD) for tools to protect the warfighter which also have applicability in the broader global health context.

We write to emphasize the importance of DoD's infectious disease research not only in promoting the safety of our servicemembers abroad, but also in supporting US global health efforts to address HIV/AIDS, malaria, tuberculosis (TB), neglected tropical diseases, antimicrobial resistance, and emerging infectious diseases, including COVID-19. This reality is aptly reflected in the motto of the Walter Reed Army Institute of Research (WRAIR), "Soldier Health, World Health." **For fiscal year 2022 (FY22), we respectfully urge the Subcommittee to sustain and protect funding for research to develop new global health technologies at DoD both within the Defense Health Program and the Congressionally Directed Medical Research Program (CDMRP), and where possible target new funds from proposed increases in Defense spending to important infectious disease research that benefits both our servicemembers and vulnerable populations overseas.**

DoD plays a unique role in the advancement of new vaccines, drugs, and health technologies that prevent and treat infectious diseases that many Americans never see up close but that our servicemembers stationed overseas experience alongside local communities. We saw this most recently with DoD's response to the 2014 Ebola outbreak in West Africa. DoD's quick work to advance the development of Ebola vaccines and treatments during troop deployment to West Africa underscores the importance of DoD research for countermeasures to address the many disease threats that may undermine operational effectiveness. The effects of this commitment continue: WRAIR, together with the National Institute of Allergy and Infectious Diseases, conducted phase 1 clinical testing of the rVSV-ZEBOV Ebola vaccine candidate, which was vital to containing the 2018-2020 Ebola outbreak in the Democratic Republic of the Congo (DRC), the second deadliest in history, underscoring the additional public health benefits of DoD's infectious disease research. It is clear that the new tools developed with

US government support were vital to the containment of this deadly outbreak and will be critical tools to mitigate the outbreaks currently affecting DRC and Guinea, both declared in February 2021.

Not only are DoD's R&D efforts for infectious diseases critical to protecting our troops overseas, but they are also important for promoting global health and global health security. Diseases like HIV/AIDS, TB, malaria, and neglected tropical diseases devastate hundreds of millions of people around the world, pose public health threats in the United States, and inhibit the economic growth of our global trading partners. In our increasingly interconnected world, infectious diseases are a plane ride—or mission deployment—away, and research at DoD yields tremendous dividends for saving lives around the world, promoting global growth and development, and ensuring global health security.

The interconnectedness of our world and our vulnerability to global public health threats have been underscored by the devastation of COVID-19, but this pandemic has also put DoD's unique capabilities in health innovation on full display. DoD has been on the cutting edge of COVID-19 R&D, directing its investments toward countermeasures that can withstand the challenges of low-resource settings, such as needleless vaccines that are stable at room temperature and diagnostics that work without advanced laboratories.

Support for DoD health research is needed for emerging and enduring health threats. In particular, malaria, which threatens the lives of nearly 3.2 billion people in tropical and poor regions of the world, is a significant threat to the operational readiness of the US military. In fact, more person-days were lost among US military personnel due to malaria than to bullets during every military campaign fought in malaria-endemic regions during the 20th century. Thanks to ongoing research at DoD, nearly all the most effective and widely used antimalarials were developed in part by US military researchers.

The study of infectious diseases, including malaria, serious bacterial infections, TB, dengue fever, leishmaniasis, and smallpox, has historically been an important component of DoD's medical research programs worldwide. While focused on protecting and treating US armed forces, the global health efforts of DoD and its partners include substantial R&D, infrastructure, and capacity-building, as well as training programs that benefit countries with few resources for health care. **DoD continues to conduct research aimed at developing solutions to global health challenges. For example:**

- The US Military Malaria Vaccine Program (USMMVP), made up of the Naval Medical Research Center Malaria Department and WRAIR Malaria Vaccine Branch, is the world's largest translational research enterprise dedicated to developing a malaria vaccine. USMMVP has led the development of vaccine candidates offering high-level and partial protection against malaria, as well as the discovery of novel protective malaria antigens and new ways to test vaccines prior to going into humans. WRAIR led early clinical development of the RTS,S vaccine in the 1990s and has been involved in the most recent clinical trials of alternative RTS,S regimens. The RTS,S malaria vaccine is the only malaria vaccine approved by the US Food and Drug Administration (FDA) and, to date, is the only vaccine to show a protective effect against malaria among young children. The vaccine is being provided to young children through national immunization programs in Ghana, Kenya, and Malawi as part of a pilot introduction that began in 2019.
- WRAIR first synthesized the antimalarial drug candidate tafenoquine, which received FDA approval in 2018 as a single-dose treatment for the radical cure (prevention of relapse) of *P. vivax* malaria, the first new treatment developed for the strain in more than 60 years.

- The US Military HIV Research Program (MHRP) continues its efforts to develop a safe and effective HIV vaccine. MHRP's partners in Thailand and Uganda are currently involved in a trial to test a promising "mosaic" HIV vaccine designed to address several HIV strains at once, one of two HIV vaccine candidates now in late-stage clinical trials in sub-Saharan Africa.
- DoD programs in leishmaniasis and dengue fever research have led to breakthroughs in treatment for these diseases.
- The Army and Navy overseas medical research laboratories are part of the vital global health research network, and the staff of the infectious disease programs have years of hands-on experience with some of the deadliest global diseases.
- The Defense Advanced Research Projects Agency (DARPA) pioneered technology that has led to electrochemical generators of chlorine that may be able to fulfill a community's needs for effective disinfectants for water or surfaces by using just salt water and a simple battery source, such as a car or motorcycle battery—an intervention that could have profound health implications for populations in low-resource settings.
- DARPA is working on developing an antibody-based technology that could provide temporary protection against COVID-19. Though not a vaccine, this tool could be a critical transition technology that provides at-risk individuals with protection against the virus for several months while a vaccine is being developed.
- The Defense Threat Reduction Agency (DTRA) is conducting groundbreaking work on vaccine and chemical reagent thermostabilization as well as point-of-care diagnostic tests for infectious diseases, with positive implications for both global health and US military health in low-resource settings.
- DTRA and the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response are collaborating with external partners to develop a novel antibiotic to treat infections caused by bacteria resistant to currently available tools. DoD is an important partner in the development of new tools to combat antimicrobial resistance, which threatens troop readiness and global health.

The advancement of global health through new innovations is bolstered by DoD's research and support of product development. Only by sustaining commitment to medical R&D will we protect servicemen and women from endemic and emerging global diseases and maintain recent gains in global health.

We urge you to work with DoD to prioritize research and product development for diseases relevant to both troop health and global health within its budget and programming plans, fund infectious disease R&D accounts as robustly as possible, and protect department-wide funding for global health R&D. Specifically, it is critical to support infectious disease research at WRAIR and the Naval Medical Research Center, including their work on chemoprophylaxis, novel vaccines for threats like malaria, disease surveillance technologies, antibiotic development, and other countermeasures for diseases of military and global health importance. We urge you to provide continued oversight to ensure that these vital infectious disease research capabilities that directly support warfighter protection are protected and sustained and consider including language in the Defense bill report directing DoD to

sustain investment at no less than FY19 levels in research for chemoprophylaxis, surveillance, vaccine development, and other countermeasures for malaria at WRAIR and the Navy Medical Research and Development Center.

We understand the unique pressures you face in setting priorities for our nation and our military. Infectious disease research protects the lives of our soldiers and millions of people around the world, fosters goodwill that enhances our national security, and creates jobs and economic growth at home. These benefits are unquestionably among the nation's highest priorities.

We stand ready to work with you on these important issues that are essential to achieving our nation's global health and security goals. Please do not hesitate to contact GHTC Director Jamie Bay Nishi at jnishi@ghtcoalition.org if you have questions or need any additional information.

Sincerely,



American Society of Tropical Medicine and Hygiene



AVAC



Boston University Social Innovation on Drug Resistance Program



Coalition for Epidemic Preparedness Innovations



Elizabeth Glaser Pediatric AIDS Foundation



Equalize Health



FIND



Global Antibiotic Research and Development Partnership



Global Health Council



Translating science
into global health impact

IAVI



Infectious Diseases Society of America



Innovative Vector Control Consortium



Medicines for Malaria Venture

Medicines for Malaria Venture



PATH



Sabin Vaccine Institute



TB Alliance

